Download presentation
Presentation is loading. Please wait.
Published byZoe Craig Modified over 7 years ago
1
Figure 1. Suppression of pro-inflammatory cytokine secretion on human intestinal epithelial Caco-2 cells CT-P13 and Remicade®. From: Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease J Crohns Colitis. 2016;11(5): doi: /ecco-jcc/jjw183 J Crohns Colitis | Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please
2
Figure 2. CT-P13 induces cell cytotoxicity and cytokine suppression via tmTNFα-mediated reverse signaling similarly to Remicade® From: Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease J Crohns Colitis. 2016;11(5): doi: /ecco-jcc/jjw183 J Crohns Colitis | Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please
3
Figure 3. CT-P13 enhances the induction of regulatory macrophages (M regs), which induce wound healing in vitro. (A) CT-P13 inhibits T-cell proliferation in an MLR to the same extent as Remicade®. (B) FACS analysis showing enhanced induction of CD14+CD206+ M regs upon Remsima® or Remicade® treatment. PBMCs from CD patients in an MLR M regs were characterized as double positive (CD14+/CD206+) cell populations of M regs by FACS analysis. (C) Representative pictures of the wound-healing assay. CT-P13 or Remicade® (10 μg/mL) -induced regulatory macrophages or CD14 negative non-regulatory macrophages from CT-P13-induced M reg culture were transferred to either previously scratched or unscratched HCT116 epithelial cells. Images were taken at t = 0 and t = 24 hours. (D) Relative percentage of wound healing observed with the different cell types. Two batches of CT-P13 and Remicade® were used in these assays. From: Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease J Crohns Colitis. 2016;11(5): doi: /ecco-jcc/jjw183 J Crohns Colitis | Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please
4
Figure 4. Expression levels of tmTNFa on various target cells and ADCC activity of CT-P13 and Remicade® against target cell type. From: Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease J Crohns Colitis. 2016;11(5): doi: /ecco-jcc/jjw183 J Crohns Colitis | Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.